Literature DB >> 22644988

Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.

Jennifer G Whisenant1, Todd E Peterson, Jacob U Fluckiger, Mohammed Noor Tantawy, Gregory D Ayers, Thomas E Yankeelov.   

Abstract

PURPOSE: The objective of this study is to determine the reproducibility of static 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG), 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT), and [(18)F]-fluoromisonidazole ((18)F-FMISO) microPET measurements, as well as kinetic parameters returned from analyses of dynamic (18)F-FLT and (18)F-FMISO data. PROCEDURES: HER2+ xenografts were established in nude mice. Dynamic data were acquired for 60 min, followed by a repeat injection and second scan 6 h later. Reproducibility was assessed for the percent-injected dose per gram (%ID/g) for each radiotracer, and with kinetic parameters (K (1) -k (4) , K ( i )) for (18)F-FLT and (18)F-FMISO.
RESULTS: The value needed to reflect a change in tumor physiology is given by the 95 % confidence interval (CI), which is ±14, ±5, and ±6 % for (18)F-FDG (n = 12), (18)F-FLT (n = 11), and (18)F-FMISO (n = 11) %ID/g, respectively. V ( d ) (=K (1) /k (2)), k (3), and K (FLT) are the most reproducible (18)F-FLT (n = 9) kinetic parameters, with 95 % CIs of ±18, ±10, and ±18 %, respectively. V ( d ) and K (FMISO) are the most reproducible (18)F-FMISO kinetic parameters (n = 7) with 95 % CIs of ±16 and ±14 %, respectively.
CONCLUSIONS: Percent-injected dose per gram measurements are reproducible and appropriate for detecting treatment-induced changes. Kinetic parameters have larger threshold values, but are potentially sufficiently reproducible to detect treatment response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22644988      PMCID: PMC3752931          DOI: 10.1007/s11307-012-0564-0

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  27 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner.

Authors:  Jonathan A Disselhorst; Maarten Brom; Peter Laverman; Cornelius H Slump; Otto C Boerman; Wim J G Oyen; Martin Gotthardt; Eric P Visser
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

Review 3.  Use of new imaging techniques to predict tumour response to therapy.

Authors:  Vanessa N Harry; Scott I Semple; David E Parkin; Fiona J Gilbert
Journal:  Lancet Oncol       Date:  2010-01       Impact factor: 41.316

4.  Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.

Authors:  Seung Jin Lee; Hye Young Kang; Seog Young Kim; Jin Hwa Chung; Seung Jun Oh; Jin-Sook Ryu; Sung-Bae Kim; Jong Soon Kang; Song-Kyu Park; Hwan Mook Kim; Myung-Hwa Kim; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 5.  Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.

Authors:  V Guarneri; E Barbieri; M V Dieci; F Piacentini; P Conte
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

6.  18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Authors:  Christoph Oehler; Joseph A O'Donoghue; James Russell; Pat Zanzonico; Sylvie Lorenzen; C Clifton Ling; Sean Carlin
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

7.  Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.

Authors:  Susan M Galbraith; Martin A Lodge; N Jane Taylor; Gordon J S Rustin; Søren Bentzen; J James Stirling; Anwar R Padhani
Journal:  NMR Biomed       Date:  2002-04       Impact factor: 4.044

8.  Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.

Authors:  Mark Muzi; David A Mankoff; John R Grierson; Joanne M Wells; Hubert Vesselle; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

9.  Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.

Authors:  Wenli Wang; Nancy Y Lee; Jens-Christoph Georgi; Manoj Narayanan; Jose Guillem; Heiko Schöder; John L Humm
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  10 in total

Review 1.  Kinetic modeling in PET imaging of hypoxia.

Authors:  Fan Li; Jesper T Joergensen; Anders E Hansen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

2.  NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System.

Authors:  Charline Lasnon; Audrey Emmanuelle Dugue; Mélanie Briand; Cécile Blanc-Fournier; Soizic Dutoit; Marie-Hélène Louis; Nicolas Aide
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

3.  Quantitative Longitudinal Imaging Reveals that Inhibiting Hedgehog Activity Alleviates the Hypoxic Tumor Landscape.

Authors:  Tshering D Lama-Sherpa; Shamik Das; Dominique C Hinshaw; Sarah C Kammerud; Patrick N Song; Heba A Alsheikh; Anna G Sorace; Rajeev S Samant; Lalita A Shevde
Journal:  Mol Cancer Res       Date:  2021-09-30       Impact factor: 6.333

Review 4.  Methods and challenges in quantitative imaging biomarker development.

Authors:  Richard G Abramson; Kirsteen R Burton; John-Paul J Yu; Ernest M Scalzetti; Thomas E Yankeelov; Andrew B Rosenkrantz; Mishal Mendiratta-Lala; Brian J Bartholmai; Dhakshinamoorthy Ganeshan; Leon Lenchik; Rathan M Subramaniam
Journal:  Acad Radiol       Date:  2015-01       Impact factor: 3.173

Review 5.  [Multiparametric and molecular imaging of breast tumors with MRI and PET/MRI].

Authors:  K Pinker; M A Marino; A Dr Meyer-Baese; T H Helbich
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

6.  Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

Authors:  Anna G Sorace; Anum K Syed; Stephanie L Barnes; C Chad Quarles; Violeta Sanchez; Hakmook Kang; Thomas E Yankeelov
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

7.  [(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.

Authors:  Keisha C McCall; Su-Chun Cheng; Ying Huang; Nancy E Kohl; Tanya Tupper; Annick D Van den Abbeele; Katherine A Zukotynski; Christopher J Sweeney
Journal:  Transl Oncol       Date:  2015-06       Impact factor: 4.243

8.  Noninvasive evaluation of 18F-FDG/18F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer.

Authors:  Mingyu Zhang; Huijie Jiang; Rongjun Zhang; Hailong Xu; Hao Jiang; Wenbin Pan; Xin Li; Yiqiao Wang; Song Wang
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

9.  Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer.

Authors:  Antti Silvoniemi; Sami Suilamo; Timo Laitinen; Sarita Forsback; Eliisa Löyttyniemi; Samuli Vaittinen; Virva Saunavaara; Olof Solin; Tove J Grönroos; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-26       Impact factor: 9.236

10.  Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine.

Authors:  Kooresh I Shoghi; Cristian T Badea; Stephanie J Blocker; Thomas L Chenevert; Richard Laforest; Michael T Lewis; Gary D Luker; H Charles Manning; Daniel S Marcus; Yvonne M Mowery; Stephen Pickup; Ann Richmond; Brian D Ross; Anna E Vilgelm; Thomas E Yankeelov; Rong Zhou
Journal:  Tomography       Date:  2020-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.